FY2030 Earnings Forecast for Ocugen Issued By HC Wainwright

Ocugen, Inc. (NASDAQ:OCGN) – HC Wainwright issued their FY2030 EPS estimates for Ocugen in a research note issued on Monday, March 9th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of $1.04 for the year. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The business had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million.

A number of other equities analysts have also issued reports on OCGN. Chardan Capital reissued a “buy” rating and set a $7.00 price target on shares of Ocugen in a research note on Thursday, March 5th. Wall Street Zen cut shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ocugen has a consensus rating of “Hold” and a consensus target price of $7.00.

Ocugen Price Performance

Shares of Ocugen stock opened at $1.77 on Tuesday. The stock has a market capitalization of $580.38 million, a price-to-earnings ratio of -7.70 and a beta of 2.75. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. Ocugen has a 1-year low of $0.52 and a 1-year high of $2.00. The firm’s 50-day moving average price is $1.59 and its two-hundred day moving average price is $1.44.

Institutional Trading of Ocugen

Several large investors have recently modified their holdings of the stock. SmartHarvest Portfolios LLC bought a new position in shares of Ocugen in the 4th quarter valued at $31,000. BNP Paribas Financial Markets grew its holdings in Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after acquiring an additional 13,326 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after purchasing an additional 24,460 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Ocugen during the 4th quarter worth about $38,000. Finally, Cora Capital Advisors LLC grew its position in shares of Ocugen by 27.5% in the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after buying an additional 6,500 shares during the last quarter. 10.27% of the stock is owned by institutional investors and hedge funds.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.